Navigation Links
DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients

CLEVELAND, Oct. 16 /PRNewswire-FirstCall/ -- DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded two new studies from European Sponsor clients. These new studies will seek to enroll a broad range of patients across both Europe as well as the Indian subcontinent.

"We are delighted to have won this new business and consider it to be a direct result of our continued hard work in providing world-class professional services around our innovative eClinical platform," said Laurence Birch, DATATRAK's Chairman of the Board. "More and more Sponsors and CROs are recognizing, and taking advantage of, the benefits of being able to conduct their drug programs on a single, unified and multi-faceted eClinical solution, rather than getting entangled in a maze of integrated clinical solutions with several third parties and solution providers. While other vendors continue to acquire disparate solutions in an effort to broaden their own offerings, we continue to see evidence that our strategy of having developed a single database eClinical solution is gaining more and more recognition."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK Exhibiting at the DIAs 3rd Annual Clinical Forum in Nice, France
2. DATATRAK Launches New Web Site
3. Advance Research Associates Joins DATATRAKs CRO Connect Program(TM)
4. DATATRAK Announces New Products and Features at DIA San Diego
5. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
6. DATATRAK International, Inc. Announces First Quarter Results for 2009
7. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
8. Keypoint Joins DATATRAKs CRO Connect Program(TM)
9. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
10. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
11. DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar SEO , ... has officially launched a sleek, mobile-ready and user-centric redesigned website. , Vivek Srivastava, ... clearly outlines the benefits that its SEO services provide to dentists and why ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. ... the nation’s leading networking organization exclusively for professional women, boasting 850,000 members and ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is excited ... plans on . The multi-carrier insurance exchange platform offers individual vision ... consumers to compare, quote and match plans to meet their needs. , ...
(Date:11/30/2015)... ... ... Stress, anxiety, illness, infection or even a need for eyeglasses can sometimes cause ... a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said that ... “Bad headaches that don’t go away, that don’t have any other reason, even ...
(Date:11/30/2015)... , ... November 30, 2015 , ... MOSI recently added ... Sea along with Back to the Jurassic to their collection of interactive exhibits within ... created dynamic worlds that will allow guests to get closer than ever to a ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Nautilus Medical Inc. today ... Management platform ( ). The release of MatrixRay ... RSNA 2015 (Radiology Society North America) in ... the U.S. --> --> ... enables access to radiology studies worldwide via a peer-to-peer ...
(Date:11/30/2015)... North America was valued ... at a CAGR of 7.6% from 2015 to 2020. --> ... million in 2014, and is expected to grow at a CAGR ... the new Market Research Report "North America Cardiac Output Monitoring Devices ... ambulatory care, others) - Analysis And Forecast To 2020", the cardiac ...
(Date:11/30/2015)... PUNE, India , November 30, ... --> --> ... deal trends for 2010 - 2015 ... activity for a range of deal ... (M&A) and strategic alliances. ...
Breaking Medicine Technology: